Melasma
☆ An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
Et ass e gemeinsame Zoustand bei asiatesche Fraen an hire fréie 40er observéiert. Déi ëmkreest Läsion op der Foto ass méi no bei Lentigo anstatt Melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Viru kuerzem ass low-fluence Q-switched Nd:YAG (LFQSNY) Laser populär ginn fir Melasma ze behandelen, besonnesch an Asien. Verschidde Studien zesummefaassen war Erausfuerderung, awer LFQSNY schéngt allgemeng effektiv a sécher fir Melasma am Verglach mat traditionelle Therapien. Allerdéngs sinn e puer Fäll vu gefleckter Hypopigmentatioun als Nebenwirkung vum LFQSNY gemellt ginn, méiglecherweis wéinst héijer Laserenergie. Aggressiv Notzung vu LFQSNY kann och zu Hyperpigmentéierung vun der Entzündung féieren, besonnesch an däischterer Hauttéin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Pigmentatiounsproblemer ginn dacks an der Primärversuergung fonnt. Allgemeng Aarte vun Hyperpigmentéierungsstéierunge enthalen post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Melasma kann net mat Laserbehandlung fir eng gewëssen Zäit geléist ginn, well et eng Krankheet ass an där Pigment kontinuéierlech produzéiert gëtt. Tranxenemesch Säure hëlleft fir d'Pigmentéierung ze reduzéieren.
○ Behandlung
A verschiddene Länner (z.B. Japan, Korea) ass mëndlech Tranexaminsäure iwwer de Konter verfügbar an ass effektiv. D'Melasma Crème mat Tranexaminsäure an Azelainsäure kann deelweis hëllefräich sinn.
Hydroquinon kann topesch fir d'Behandlung vun Hyperpigmentatioun benotzt ginn, awer d'FDA huet d'OTC Produkter mat Hydroquinon ab 2020 gestoppt.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma